Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Tamoxifen Is a Potent Inhibitor of Cholesterol Esterification and Prevents the Formation of Foam Cells

Philippe de Medina, Bruno L. Payré, José Bernad, Isabelle Bosser, Bernard Pipy, Sandrine Silvente-Poirot, Gilles Favre, Jean-Charles Faye and Marc Poirot
Journal of Pharmacology and Experimental Therapeutics March 2004, 308 (3) 1165-1173; DOI: https://doi.org/10.1124/jpet.103.060426
Philippe de Medina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno L. Payré
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Bernad
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabelle Bosser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Pipy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandrine Silvente-Poirot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles Favre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Charles Faye
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Poirot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Tamoxifen is a selective estrogen receptor modulator (SERM) used for the treatment and prevention of breast cancer. Tamoxifen has been reported to protect against the progression of coronary artery diseases in human and different atherosclerosis animal models by blocking the appearance of the atheromatous plaque. However, the molecular mechanism of this effect remains unknown. Acyl-CoA:cholesterol acyl transferase (ACAT) catalyzes the biosynthesis of cholesteryl esters, which are the major lipids found in the atheromatous plaque. In this paper we have tested whether ACAT might be inhibited by tamoxifen. We show, using molecular modeling, that tamoxifen displays three-dimensional structural homology with Sah 58-035 (3-[decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]-propanamide), a prototypical inhibitor of ACAT. We report that tamoxifen inhibits ACAT in a concentration-dependent manner on rat liver microsomal extract. We show that the presence on estrogen receptor ligands of a backbone isosteric to the diphenyl ethane backbone of Sah 58-035 constitutes a pharmacophore for ACAT inhibition. More importantly, tamoxifen was able to inhibit ACAT on intact macrophages stimulated with acetylated low-density lipoproteins and blocked the formation of foam cells, a step that precedes the formation of the atheromatous plaque. This work constitutes the first evidence that tamoxifen is an inhibitor of ACAT and foam cell formation at therapeutic doses and that this may account for its atheroprotective action.

Footnotes

  • This work was supported by the Institut National de la Recherche Médicale, a grant from the Association pour la Recherche sur le Cancer (ARC 5648), and a grant from the Caisse d'Assurance Maladie des Profession Libérales Provinces (Paris) and Affichem. P.D.M. was supported by the Ministère de la Recherche et de la Technologie.

  • DOI: 10.1124/jpet.103.060426.

  • ABBREVIATIONS: ACAT, acyl-CoA:cholesterol acyl transferase; ER, estrogen receptor; DPE, diphenylethane; DPM, diphenylmethane; RPM, rat peritoneal macrophage; LDL, low-density lipoprotein; AcLDL, acetylated low-density lipoprotein; Sah 58-035, 3-[decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]-propanamide; RU 39,411, 11β-[4-N,N-[diethylaminoethoxy]phenyl]-estra-1,3,5(10)-triene-3,17β-diol; RU 58,668, 11β-[[[(4,4,5,5,5,-pentafluoropentyl)sulfonyl]pentyloxy]phenyl]-estra-1,3,5(10)-triene-3,17β-diol; PBPE, 1-[2-(4-benzyl-phenoxy)-ethyl]-N-pyrrolidine hydrochloride; DMBPE, [2-(4-benzyl-phenoxy)-ethyl]-N,N-dimethyl-amine hydrochloride; TLC, thin-layer chromatography; ICI 182,780, Faslodex (fulvestrant); DMEM, Dulbecco's modified Eagle's medium; CI-628, nitromiphene citrate [α-(4-N-pyrrolidinethoxyl)phenyl-4-methoxy-α-nitrostilbene]); ICI 164,384, (N-n-butyl-N-methyl-11-[3,17β-di-hydroxyestra-1,3,5(10)-trien-7α-yl]-undecanamide.

    • Received September 24, 2003.
    • Accepted November 12, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 308 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 308, Issue 3
1 Mar 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Tamoxifen Is a Potent Inhibitor of Cholesterol Esterification and Prevents the Formation of Foam Cells
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Tamoxifen Is a Potent Inhibitor of Cholesterol Esterification and Prevents the Formation of Foam Cells

Philippe de Medina, Bruno L. Payré, José Bernad, Isabelle Bosser, Bernard Pipy, Sandrine Silvente-Poirot, Gilles Favre, Jean-Charles Faye and Marc Poirot
Journal of Pharmacology and Experimental Therapeutics March 1, 2004, 308 (3) 1165-1173; DOI: https://doi.org/10.1124/jpet.103.060426

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleCARDIOVASCULAR

Tamoxifen Is a Potent Inhibitor of Cholesterol Esterification and Prevents the Formation of Foam Cells

Philippe de Medina, Bruno L. Payré, José Bernad, Isabelle Bosser, Bernard Pipy, Sandrine Silvente-Poirot, Gilles Favre, Jean-Charles Faye and Marc Poirot
Journal of Pharmacology and Experimental Therapeutics March 1, 2004, 308 (3) 1165-1173; DOI: https://doi.org/10.1124/jpet.103.060426
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Anti-apoptotic effect of rosuvastatin via autophagy
  • Improved Assessment of Cardiovascular Safety Data
  • G6PD, DNA methylation, and PAH
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics